文献速递胸部肿瘤

晚期ALK重排非小细胞肺癌中EML4-ALK融合变体的蛋白稳定性差异及其对不同ALK抑制剂的临床反应

Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer.
PubMed 文献 · Ann Oncol · 2017-01-01

该回顾性研究通过多重逆转录PCR检测54例晚期ALK重排阳性非小细胞肺癌的EML4-ALK融合变体,按蛋白稳定性分为变体1/2/其他组和变体3a/b组,评估变体状态与克唑替尼、阿来替尼或色瑞替尼临床反应的相关性,并建立变体表达系统分析敏感性。结果显示变体3a/b组接受克唑替尼患者的2年无进展生存率显著低于变体1/2/其他组(26.4% vs 76.0%,P=0.034)。

要点

  • EML4-ALK变体3a/b是最常见类型(44.4%),其次为变体1(33.3%)和变体2(11.1%)。
  • 克唑替尼治疗患者中,变体3a/b组2年PFS率26.4% vs 变体1/2/其他组76.0%(P=0.034)。
  • 所有克唑替尼、阿来替尼或色瑞替尼治疗患者中,两组2年PFS率差异无统计学意义(P=0.108)。

核心结论

  • EML4-ALK变体3a/b组可能是临床ALK抑制剂耐药的主要来源。
  • EML4-ALK融合的变体特异性基因型有助于更精确地对晚期非小细胞肺癌患者进行分层。

研究设计与样本

  • 回顾性研究,通过多重逆转录PCR检测54例晚期ALK重排阳性非小细胞肺癌的EML4-ALK融合变体。
  • 按蛋白稳定性将患者分为变体1/2/其他组和变体3a/b组,评估变体状态与克唑替尼、阿来替尼或色瑞替尼临床反应的相关性。
  • 建立EML4-ALK变体表达系统,分析变体对ALK抑制剂的敏感性模式。

主要发现

  • 54例肿瘤中,EML4-ALK变体3a/b占44.4%,变体1占33.3%,变体2占11.1%。
  • 克唑替尼治疗患者中,变体1/2/其他组2年PFS率为76.0%(95%CI 56.8-100),变体3a/b组为26.4%(95%CI 10.5-66.6),P=0.034。
  • 所有克唑替尼、阿来替尼或色瑞替尼治疗患者中,变体1/2/其他组2年PFS率为69.0%(95%CI 49.9-95.4),变体3a/b组为32.7%(95%CI 15.6-68.4),P=0.108。
  • 体外实验中,携带变体3a或5a的细胞对ALK抑制剂耐药,半数抑制浓度升高超过10倍。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anaplastic lymphoma kinase (ALK) inhibition using crizotinib has become the standard of care in advanced ALK-rearranged non-small cell lung cancer (NSCLC), but the treatment outcomes and duration of response vary widely. Echinoderm microtubule-associated protein-like 4 (EML4)-ALK is the most common translocation, and the fusion variants show different sensitivity to crizotinib in vitro. However, there are only limited data on the specific EML4-ALK variants and clinical responses of patients to various ALK inhibitors. PATIENTS AND METHODS: By multiplex reverse-transcriptase PCR, which detects 12 variants of known EML4-ALK rearrangements, we retrospectively determined ALK fusion variants in 54 advanced ALK rearrangement-positive NSCLCs. We subdivided the patients into two groups (variants 1/2/others and variants 3a/b) by protein stability and evaluated correlations of the variant status with clinical responses to crizotinib, alectinib, or ceritinib. Moreover, we established the EML4-ALK variant-expressing system and analyzed patterns of sensitivity of the variants to ALK inhibitors. RESULTS: Of the 54 tumors analyzed, EML4-ALK variants 3a/b (44.4%) was the most common type, followed by variants 1 (33.3%) and 2 (11.1%). The 2-year progression-free survival (PFS) rate was 76.0% [95% confidence interval (CI) 56.8-100] in group EML4-ALK variants 1/2/others versus 26.4% (95% CI 10.5-66.6) in group variants 3a/b (P = 0.034) among crizotinib-treated patients. Meanwhile, the 2-year PFS rate was 69.0% (95% CI 49.9-95.4) in group variants 1/2/others versus 32.7% (95% CI 15.6-68.4) in group variants 3a/b (P = 0.108) among all crizotinib-, alectinib-, and ceritinib-treated patients. Variant 3a- or 5a-harboring cells were resistant to ALK inhibitors with >10-fold higher half maximal inhibitory concentration in vitro. CONCLUSION: Our findings show that group EML4-ALK variants 3a/b may be a major source of ALK inhibitor resistance in the clinic. The variant-specific genotype of the EML4-ALK fusion allows for more precise stratification of patients with advanced NSCLC.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Woo CG, Seo S, Kim SW, et al. Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer. Ann Oncol. 2017. PMID: 28039177. doi:10.1093/annonc/mdw693

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。